ReNeuron’s recent clinical progress has been encouraging and we continue to see significant value within the group. We update our forecasts this morning following the group’s FY 2017 results. We remain upbeat and look forward to newsflow from the clinical pipeline over the next 18 months (retinitis pigmentosa Phase I/II data, Phase II cone-rod dystrophy trial commencement and initiation of a Phase III trial in stroke).
17 Aug 2017
N+1 Singer - ReNeuron Group - Pipeline continues to progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - ReNeuron Group - Pipeline continues to progress
ReNeuron Group plc (RENE:LON) | 0 0 0.0% | Mkt Cap: 1.74m
- Published:
17 Aug 2017 -
Author:
Sheena Berry -
Pages:
4
ReNeuron’s recent clinical progress has been encouraging and we continue to see significant value within the group. We update our forecasts this morning following the group’s FY 2017 results. We remain upbeat and look forward to newsflow from the clinical pipeline over the next 18 months (retinitis pigmentosa Phase I/II data, Phase II cone-rod dystrophy trial commencement and initiation of a Phase III trial in stroke).